Abstract
Objective: To analyse all available evidence to validate the effectiveness of a local intervention in the treatment of dyspareunia in breast cancer survivors (BCS). Methods: We searched the Institute of Scientific Information Web of Knowledge, MEDLINE, PubMed, Scopus, and Cochrane databases for all articles published in peer-reviewed journals up to April 2019. The PICOS standards were: (population) BCS with dyspareunia; (intervention) any type of vulvovaginal treatment; (main outcome) frequency and severity of dyspareunia; (study design) clinical studies. Results: The literature search strategy identified 252 articles, of which 233 were excluded at various stages of the search. Finally, we systematically reviewed 19 studies, 8 with local hormonal therapies, 7 with local non-hormonal therapies, 3 with laser therapy, and 1 with other interventions. Of the studies, 7 were randomized control trials and 11 were prospective observations. Most of the interventions were shown to be effective and safe in the improvement of dyspareunia. Conclusion: In addition to the traditional options already analysed in other current reviews, other interesting options are highlighted (such as laser or local dehydroepiandrosterone [DHEA]). Further work on dyspareunia should make use of high-quality trials with large numbers of samples to obtain evidence that could adequately demonstrate key methodological characteristics and harmful effects.
References
1.
De Angelis
R
, Sant
M
, Coleman
MP
, Francisci
S
, Baili
P
, Pierannunzio
D
, et al.; EUROCARE-5 Working Group
. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE—5-a population-based study
. Lancet Oncol
. 2014
Jan
;15
(1
):23
–34
.
[PubMed]
1470-20452.
Hashim
D
, Boffetta
P
, La Vecchia
C
, Rota
M
, Bertuccio
P
, Malvezzi
M
, et al. The global decrease in cancer mortality: trends and disparities
. Ann Oncol
. 2016
May
;27
(5
):926
–33
.
[PubMed]
0923-75343.
Sánchez-Borrego
R
, Mendoza
N
, Beltrán
E
, Comino
R
, Allué
J
, Castelo-Branco
C
, et al. Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients
. Maturitas
. 2013
Jul
;75
(3
):294
–300
.
[PubMed]
0378-51224.
Mendoza
N
, Molero
F
, Criado
F
, Cornellana
MJ
, González
E
; Sexuality In Breast Cancer Survivors Group
. Sexual health after breast cancer: Recommendations from the Spanish Menopause Society, Spanish Federation of Societies of Sexology, Spanish Society of Primary Care Physicians and Spanish Society of Medical Oncology
. Maturitas
. 2017
;105
:126
–31
.
[PubMed]
0378-51226.
Kendall
A
, Dowsett
M
, Folkerd
E
, Smith
I
. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors
. Ann Oncol
. 2006
Apr
;17
(4
):584
–7
.
[PubMed]
0923-75347.
Biglia
N
, Peano
E
, Sgandurra
P
, Moggio
G
, Panuccio
E
, Migliardi
M
, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study
. Gynecol Endocrinol
. 2010
Jun
;26
(6
):404
–12
.
[PubMed]
0951-35908.
Pfeiler
G
, Glatz
C
, Königsberg
R
, Geisendorfer
T
, Fink-Retter
A
, Kubista
E
, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients
. Climacteric
. 2011
Jun
;14
(3
):339
–44
.
[PubMed]
1369-71379.
Witherby
S
, Johnson
J
, Demers
L
, Mount
S
, Littenberg
B
, Maclean
CD
, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study
. Oncologist
. 2011
;16
(4
):424
–31
.
[PubMed]
1083-715910.
Dahir
M
, Travers-Gustafson
D
. Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy
. Sex Med
. 2014
Apr
;2
(1
):8
–15
.
[PubMed]
2050-116111.
Donders
G
, Neven
P
, Moegele
M
, Lintermans
A
, Bellen
G
, Prasauskas
V
, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study
. Breast Cancer Res Treat
. 2014
Jun
;145
(2
):371
–9
.
[PubMed]
0167-680612.
Melisko
ME
, Goldman
ME
, Hwang
J
, De Luca
A
, Fang
S
, Esserman
LJ
, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial
. JAMA Oncol
. 2017
Mar
;3
(3
):313
–9
.
[PubMed]
2374-243713.
Barton
DL
, Sloan
JA
, Shuster
LT
, Gill
P
, Griffin
P
, Flynn
K
, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)
. Support Care Cancer
. 2018
Feb
;26
(2
):643
–50
.
[PubMed]
0941-435514.
Juraskova
I
, Jarvis
S
, Mok
K
, Peate
M
, Meiser
B
, Cheah
BC
, et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer
. J Sex Med
. 2013
Oct
;10
(10
):2549
–58
.
[PubMed]
1743-609515.
Lee
YK
, Chung
HH
, Kim
JW
, Park
NH
, Song
YS
, Kang
SB
. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial
. Obstet Gynecol
. 2011
Apr
;117
(4
):922
–7
.
[PubMed]
0029-784416.
Goetsch
MF
, Lim
JY
, Caughey
AB
. A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial
. J Clin Oncol
. 2015
Oct
;33
(30
):3394
–400
.
[PubMed]
0732-183X17.
Hickey
M
, Marino
JL
, Braat
S
, Wong
S
. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer
. Breast Cancer Res Treat
. 2016
Jul
;158
(1
):79
–90
.
[PubMed]
0167-680618.
Juliato
PT
, Rodrigues
AT
, Stahlschmidt
R
, Juliato
CR
, Mazzola
PG
. Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?
Climacteric
. 2017
Feb
;20
(1
):62
–6
.
[PubMed]
1369-713719.
Kim
YH
, Park
S
, Lee
M
, Hahn
S
, Jeon
MJ
. Effect of a pH-Balanced Vaginal Gel on Dyspareunia and Sexual Function in Breast Cancer Survivors Who Were Premenopausal at Diagnosis: A Randomized Controlled Trial
. Obstet Gynecol
. 2017
May
;129
(5
):870
–6
.
[PubMed]
0029-784420.
Chatsiproios
D
, Schmidts-Winkler
IM
, König
L
, Masur
C
, Abels
C
. Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study
. PLoS One
. 2019
Jan
;14
(1
):e0210967
.
[PubMed]
1932-620321.
Pieralli
A
, Fallani
MG
, Becorpi
A
, Bianchi
C
, Corioni
S
, Longinotti
M
, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors
. Arch Gynecol Obstet
. 2016
Oct
;294
(4
):841
–6
.
[PubMed]
0932-006722.
Gambacciani
M
, Levancini
M
. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors
. Menopause
. 2017
Mar
;24
(3
):316
–9
.
[PubMed]
1072-371423.
Becorpi
A
, Campisciano
G
, Zanotta
N
, Tredici
Z
, Guaschino
S
, Petraglia
F
, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects
. Lasers Med Sci
. 2018
Jul
;33
(5
):1047
–54
.
[PubMed]
0268-892124.
Hersant
B
. SidAhmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, Bosc R, Niddam J, Hermeziu O, La Padula S, Meningaud JP. Efficacy of injecting platelet concentrates combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with a history of breast cancer: a phase 2 pilot study
. Menopause
. 2018
;25
(10
):1124
–30
.
[PubMed]
1072-371425.
Candy
B
, Jones
L
, Vickerstaff
V
, Tookman
A
, King
M
. Interventions for sexual dysfunction following treatments for cancer in women
. Cochrane Database Syst Rev
. 2016
Feb
;2
:CD005540
.
[PubMed]
1469-493X26.
Chang
YC
, Chang
SR
, Chiu
SC
. Sexual Problems of Patients With Breast Cancer After Treatment: A Systematic Review
. Cancer Nurs
. 2018
Apr
;•••
: ; [Epub ahead of print
].
[PubMed]
0162-220X27.
Maiorino
MI
, Chiodini
P
, Bellastella
G
, Giugliano
D
, Esposito
K
. Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index
. Endocrine
. 2016
Nov
;54
(2
):329
–41
.
[PubMed]
1355-008X28.
Seav
SM
, Dominick
SA
, Stepanyuk
B
, Gorman
JR
, Chingos
DT
, Ehren
JL
, et al. Management of sexual dysfunction in breast cancer survivors: a systematic review
. Womens Midlife Health
. 2015
Nov
;1
(1
):9
.
[PubMed]
2054-269029.
Bachmann
GA
, Ramachandra
S
. Management of sexual dysfunction in breast cancer survivors: a systematic review editorial---looking back to move ahead
. Womens Midlife Health
. 2015
Nov
;1
(1
):8
.
[PubMed]
2054-269030.
Mazzarello
S
, Hutton
B
, Ibrahim
MF
, Jacobs
C
, Shorr
R
, Smith
S
, et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials
. Breast Cancer Res Treat
. 2015
Jul
;152
(1
):1
–8
.
[PubMed]
0167-680631.
Jing
L
, Zhang
C
, Li
W
, Jin
F
, Wang
A
. Incidence and severity of sexual dysfunction among women with breast cancer: a meta-analysis based on female sexual function index
. Support Care Cancer
. 2019
Apr
;27
(4
):1171
–80
.
[PubMed]
0941-435532.
Farrell
R
; American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice
. ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer
. Obstet Gynecol
. 2016
Mar
;127
(3
):e93
–6
.
[PubMed]
0029-784433.
Labrie
F
, Archer
DF
, Koltun
W
, Vachon
A
, Young
D
, Frenette
L
, et al.; VVA Prasterone Research Group
. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause
. Menopause
. 2016
Mar
;23
(3
):243
–56
.
[PubMed]
1072-371434.
Kenemans
P
, Bundred
NJ
, Foidart
JM
, Kubista
E
, von Schoultz
B
, Sismondi
P
, et al.; LIBERATE Study Group
. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
. Lancet Oncol
. 2009
Feb
;10
(2
):135
–46
.
[PubMed]
1470-2045© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
